This site is intended for U.S. Healthcare Professionals only.

  • U.S. Full Prescribing Information |
  • Medication Guide |
  • Indication

    Indication

    SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

    Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

Resources for your practice
and patients

You're there for your patients—and we’re here for you. Whether it’s resources
for your practice or materials for your patients to help guide them along their
treatment path, we have you covered.

Resources for your practice
and patients

You're there for your patients—and we’re here for you. Whether it’s resources
for your practice or materials for your patients to help guide them along their
treatment path, we have you covered.

Getting started

Simply committed to patient support

We’re working to ensure that eligible patients are able to access their medication by offering affordability programs and individualized assistance.

Patient Access Support

Getting Started on SOTYKTU
If your patients need guidance when starting SOTYKTU or are looking for assistance with the Co-Pay program, you can help by providing the following resources.
Co-Pay Assistance Program
Eligible patients with commercial insurance may pay as little as $0 a month* for SOTYKTU. Share this information with your patients to see if they are eligible.
*If your patient is uninsured or underinsured, call and we can help to determine whether there may be additional resources that can assist with access and reimbursement needs.
Advocacy groups for you
Interested in staying in the know and connecting with advocacy groups?
Visit the Advocacy page to get more information.
Bristol Myers Squibb™ Logo

SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU
logo
are trademarks of Bristol-Myers Squibb Company.

Otezla is a registered trademark of Amgen Inc.

© 2023 Bristol-Myers Squibb Company.

1787-US-2300483 07/23

1787-US-2300303 06/23

1787-US-2300737 10/23

1787-US-2300483 07/23

1787-US-2300303 06/23